"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
Descriptor ID |
D000069552
|
MeSH Number(s) |
D02.886.778.727 D03.383.533.640.713 D03.383.903.727
|
Concept/Terms |
Rivaroxaban- Rivaroxaban
- 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".
Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".
This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 0 | 1 | 1 |
2017 | 0 | 3 | 3 |
2018 | 1 | 1 | 2 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2022 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rivaroxaban" by people in Profiles.
-
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. Am Heart J. 2023 06; 260:124-140.
-
Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban. Arch Pathol Lab Med. 2022 01 02; 146(2):145-153.
-
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. J Am Heart Assoc. 2020 10 20; 9(19):e017316.
-
Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. Am J Med. 2020 05; 133 Suppl 1:1-27.
-
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 2019 09; 50(9):2477-2485.
-
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty. J Am Acad Orthop Surg. 2018 Oct 01; 26(19):698-705.
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
-
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 12; 117(12):2415-2424.
-
Antithrombotic Therapy for Venous Thromboembolic Disease. JAMA. 2017 05 16; 317(19):2008-2009.
-
Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants. Heart Vessels. 2017 Oct; 32(10):1227-1235.